10 results about "Receptor antibody" patented technology

This invention relates to a novel use of IL-1β-ligand / IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and / or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and / or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and / or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

Provided is a heterohybridoma-based method of generating recombinant rabbit monoclonal antibodies, recombinant anti-IL-6 receptor-alpha (IL-6Rα) antibodies generated using such methods, and immune assay methods kits employing such antibodies.

The present invention relates to immunoglobulins, such as immunoconjugates, comprising an ActRII receptor antibody and a GLP-1 agonist molecule, such as a GLP-1 agonist peptide. Such constructs are useful in the treatment of numerous diseases and disorders, including metabolic disorders such as obesity, diabetes, and others.

Provided herein are antigen binding proteins that specifically bind to interleukin-4 receptor (IL4R), their compositions and methods of use. Also provided herein are methods of using the IL4R antigen binding proteins for treatment of allergic or inflammatory diseases.

The present application relates to immunoglobulins, such as immunoconjugates, comprising an ActRII receptor antibody and an agonistic GLP-1 molecule, such as an agonistic GLP-1 peptide. Such constructs are useful for treating a variety of diseases and conditions, including metabolic conditions, such as obesity, diabetes, and the like.

The present invention relates to a novel therapeutic agent capable of treating muscle diseases, metabolic diseases, and bone diseases by simultaneously inhibiting the activin type II receptor and myostatin. Specifically, the invention relates to a bispecific protein comprising an anti-ActRII antibody and an anti-Myostatin antibody, and the use thereof. The simultaneous inhibition of the activin type II receptor and myostatin according to the present invention exhibits excellent effects of muscle growth and bone differentiation as well as weight loss; thus, it resolves the problem of muscle loss, which is a side effect of existing anti-obesity treatments, and can effectively improve various metabolic diseases. Therefore, the bispecific protein of the present invention can be utilized in various fields for the improvement and treatment of muscle diseases, metabolic diseases, and bone diseases.

The present invention relates to a prolactin receptor antibody and its applications, and more specifically to an antibody or its antigen-binding fragment that targets PRLR, or a variant that retains its PRLR-binding activity while having at least 85% sequence identity with the antibody or its antigen-binding fragment, wherein the antibody targets an extracellular segment that targets the prolactin receptor. The antibody of the present invention binds to PRLR with high affinity.

In one non-limiting embodiment, the present disclosure is an antibody-containing formulation comprising an anti-IL-6 receptor antibody as an active ingredient, and contains histidine-aspartate buffer or histidine-glutamate buffer, Poloxamer 188, and arginine, and has a pH of 5.5 to 6.6. In one non-limiting embodiment, the present disclosure is a method of stabilizing an antibody-containing solution, a method of suppressing antibody association (e.g., dimerization), and a method of suppressing the generation of insoluble particles, wherein L-aspartic acid or L-glutamic acid, and optionally, Poloxamer 188 are added.

This invention belongs to the field of biotechnology and provides an antibody or its antigen-binding fragment against the urokinase plasminogen activator receptor and its applications. The antibody or its antigen-binding fragment of this invention comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region includes heavy chain complementarity-determining regions HCDR1, HCDR2, and HCDR3, and the light chain variable region includes light chain complementarity-determining regions LCDR1, LCDR2, and LCDR3. The antibody or its antigen-binding fragment of this invention can bind with high affinity to human uPAR protein and can induce an anti-tumor specific immune response.

This disclosure provides masked anti-tyrosine-protein kinase membrane receptor antibody-drug conjugate structures. The antibody-drug conjugate structures include branched linkers, with two or more payloads bound to the antibody for each branched linker. In addition, this disclosure also encompasses compounds and methods for producing such conjugates. In addition, this disclosure also encompasses methods for using the conjugates. In some embodiments, such ROR-ADCs bind to the same human ROR epitope as the antibody containing the heavy chain variable region (VH) and light chain variable region (VL) described herein.